P87 - A national multicenter registration of treatment with omalizumab in Danish asthmatic children
© Spangenberg et al; licensee BioMed Central Ltd. 2014
Published: 28 February 2014
In Denmark, Omalizumab is approved for treating children with severe persistent allergic asthma older than 6 years of age. No systematic registration of the efficacy in the Danish child population according to asthma symptoms or the efficacy on co-morbid allergic symptoms exists. A broad panel of outcome measures is necessary to evaluate the efficacy of Omalizumab treatment.
To provide a standardized systematic registration in order to create a database enrolling children with severe allergic asthma treated with Omalizumab.
Method and study design
A national multicenter registration and follow-up study based on children with clinical persistent severe allergic asthma including both retrospective and prospective registration.
Children, 6-18 years of age, with severe persistent allergic asthma according to GINA treated with Omalizumab.
A broad panel of outcome measures is scheduled at baseline and during treatment:
Quality of life score. (Juniper)
Rhinitis score, R-RTSS
The monitoring plan and follow-up programme will be presented in a flowchart.
We believe that a national systematic registration will increase knowledge regarding efficacy of Omalizumab treatment in this rare group of severe allergic asthmatic children.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.